$Veeva(VEEV)$ @Trade Feed Deco-To The Moon - Tiger Brokers Online Investing Community - To The Moon

$Veeva(VEEV)$ @Trade Feed Decoder

VEEV

12-17 23:07

USVeeva

Side	Price \| Filled	Realized P&L
Buy Open	220.00 0	-0.92% Holding

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Trade Feed Decoder
12-18 00:50
Trade Feed Decoder
Analysis of VEEV Trade: The -0.75% loss on this Veeva trade suggests short-term volatility exposure in a stock known for its healthcare SaaS specialization. While VEEV typically attracts investors seeking stable growth in pharma tech, recent sector headwinds (e.g., delayed drug approvals or cloud spending scrutiny) might have impacted momentum. The entry at $220 aligns with its 50-day moving average support zone, indicating a potential mean-reversion attempt. However, the minimal loss implies either tight stop-loss discipline or limited position sizing, reflecting cautious risk management. Traders might note Veeva's mixed fundamentals (23% YoY revenue growth but declining operating margins) when evaluating such tactical entries. This trade underscores the importance of timing in momentum-driven tech healthcare names amid shifting regulatory sentiment.

Leave a comment

1

1

1

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":511834261156000,"tweetId":"511834261156000","gmtCreate":1765984086261,"gmtModify":1766074588462,"author":{"id":3568161254291931,"idStr":"3568161254291931","authorId":3568161254291931,"authorIdStr":"3568161254291931","name":"Gunners80","avatar":"https://community-static.tradeup.com/news/f8d00386d87e0c8e3a012fbf50f37511","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.05.26","exceedPercentage":"93.37%","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":1620,"starInvestorFlag":true,"fullDisclosureFlag":true,"starInvestorFollowerNum":1377,"starInvestorOrderShareNum":2500,"userFollowInvestorFlag":false,"orderNotificationFlag":false,"ror":30.63,"showRor":true,"investmentPhilosophy":"Long term dip buying for investment\nprice action trading using options","winRationPercentage":77.366255,"tradeVolumeEst":0},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><a href=\"https://ttm.financial/S/VEEV\">$Veeva(VEEV)$&nbsp;</a><a href=\"https://ttm.financial/U/10000000000011061\">@Trade Feed Decoder</a></body></html>","htmlText":"<html><head></head><body><a href=\"https://ttm.financial/S/VEEV\">$Veeva(VEEV)$&nbsp;</a><a href=\"https://ttm.financial/U/10000000000011061\">@Trade Feed Decoder</a></body></html>","text":"$Veeva(VEEV)$ @Trade Feed Decoder","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":1,"favoriteSize":0,"link":"https://ttm.financial/post/511834261156000","repostId":0,"isVote":1,"tweetType":1,"viewCount":117,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["VEEV"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":true,"orderData":{"uuid":"3568161254291931","orderId":"41560877528517632","kind":"TRADE","symbol":"VEEV","secType":"STK","symbolHtmlTag":"<a href=\"https://ttm.financial/S/VEEV\">$Veeva(VEEV)$&nbsp;</a>","symbolHtmlTagHref":"https://ttm.financial/S/VEEV","symbolName":"Veeva","market":"US","action":"BUY","currency":"USD","symbolLogo":"","showFilledQuantity":true,"nameCN":"Veeva","orderType":"LMT","filledQuantityFinal":0.2,"avgFillPrice":220,"createTime":1765984073,"filledQuantity":"2","filledQuantityScale":"1","openFlag":true,"side":"DEBIT","contractMajorDescription":"Veeva","contractExtraDescription":"VEEV","legs":[],"completedFlag":false,"orderPnl":{"openRealizedPnlPercent":0,"openUnrealizedPnlPercent":-0.0092},"quickOrderFlag":false},"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":["订单分享帖"],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":17,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":511847148515832,"commentId":"511847148515832","gmtCreate":1765990236677,"gmtModify":1765990977247,"authorId":10000000000011060,"author":{"id":10000000000011060,"idStr":"10000000000011061","authorId":10000000000011060,"name":"Trade Feed Decoder","avatar":"https://community-static.tradeup.com/news/4dc8fec78bad5acffbf563bdbc6bc8ed","vip":4,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":511834261156000,"objectIdStr":"511834261156000","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"Analysis of VEEV Trade: The -0.75% loss on this Veeva trade suggests short-term volatility exposure in a stock known for its healthcare SaaS specialization. While VEEV typically attracts investors seeking stable growth in pharma tech, recent sector headwinds (e.g., delayed drug approvals or cloud spending scrutiny) might have impacted momentum. The entry at $220 aligns with its 50-day moving average support zone, indicating a potential mean-reversion attempt. However, the minimal loss implies either tight stop-loss discipline or limited position sizing, reflecting cautious risk management. Traders might note Veeva's mixed fundamentals (23% YoY revenue growth but declining operating margins) when evaluating such tactical entries. This trade underscores the importance of timing in momentum-driven tech healthcare names amid shifting regulatory sentiment.","text":"Analysis of VEEV Trade: The -0.75% loss on this Veeva trade suggests short-term volatility exposure in a stock known for its healthcare SaaS specialization. While VEEV typically attracts investors seeking stable growth in pharma tech, recent sector headwinds (e.g., delayed drug approvals or cloud spending scrutiny) might have impacted momentum. The entry at $220 aligns with its 50-day moving average support zone, indicating a potential mean-reversion attempt. However, the minimal loss implies either tight stop-loss discipline or limited position sizing, reflecting cautious risk management. Traders might note Veeva's mixed fundamentals (23% YoY revenue growth but declining operating margins) when evaluating such tactical entries. This trade underscores the importance of timing in momentum-driven tech healthcare names amid shifting regulatory sentiment.","html":"Analysis of VEEV Trade: The -0.75% loss on this Veeva trade suggests short-term volatility exposure in a stock known for its healthcare SaaS specialization. While VEEV typically attracts investors seeking stable growth in pharma tech, recent sector headwinds (e.g., delayed drug approvals or cloud spending scrutiny) might have impacted momentum. The entry at $220 aligns with its 50-day moving average support zone, indicating a potential mean-reversion attempt. However, the minimal loss implies either tight stop-loss discipline or limited position sizing, reflecting cautious risk management. Traders might note Veeva's mixed fundamentals (23% YoY revenue growth but declining operating margins) when evaluating such tactical entries. This trade underscores the importance of timing in momentum-driven tech healthcare names amid shifting regulatory sentiment.","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"hot","coins":0,"score":0,"disclaimerFlag":true,"disclaimerType":1,"specialCommentTag":"AI_ANALYSE"}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/511834261156000"}